Krebs-Immuntherapie: Antworten auf häufig gestellte Fragen

Unser Gesprächspartner: Prof. Dr. rer. nat. Volker Schirrmacher

• Literatur

• 1 Huber C, Rammensee HG, Wölfel T, Britten CM. Hrsg. Krebsimmuntherapien. Köln: Deutscher Ärzte-Verlag; 2008
• 2 Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immuno-editing. Immunity 2004; 21: 137-148
• 3 Constantino J, Gomes C. et al. Dendritic cell-based immunotherapy: a basic review and recent advances. Immunological Research 2017; 65: 798-810
• 4 Kleponis J, Skelton R, Zheng L. Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors. Cancer Biol Med 2005; 12: 201-208
• 5 Huang J, Liu F, Liu Z. et al. Immune checkpoint in glioblastoma: promising and challenging. Front Pharmacol 2017; 8: 242
• 6 Rojas JJ, Sampath P, Hou W, Thorne SH. Defining effective combinations of immune checkpoint blockade and oncolytic virotherapy. Clin Cancer Res 2015; 21: 5543-5551
• 7 Krebsinformationsdienst. Immuntherapien. Stand: 1.8.2017 https://www.krebsinformationsdienst.de/behandlung/impfen-gegen-krebs.php#top
• 8 Fournier P, Schirrmacher V. Randomized clinical studies of anti-tumor vaccination: State of the art in 2008. Expert Reviews Vaccines 2009; 8: 51-66
• 9 Bobisse S, Foukas PG, Coukos G, Harari A. Neoantigen-based cancer immunotherapy. Ann Transl Med 2016; 4: 262
• 10 Guo ZS, Liu Z, Kowalsky S. et al. Oncolytic immunotherapy: Conceptual evolution, current strategies, and future perspectives. Front Immunol 2017; 8: 555
• 11 Lundstrom K. New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy. Biologics: Targets and Therapy 2018; 12: 43-60
• 12 Lee P, Gujar S. Potentiating prostate cancer immunotherapy with oncolytic viruses. Nat Rev Urol 2018; 15: 235-250. doi: 10.1038/nrurol 2018.10
• 13 Rosenberg SA. CCR 20th Anniversary commentary: Autologous T cells – The ultimate personalized drug for the immunotherapy of human cancer. Clin Cancer Res 2015; 21: 5409-5411
• 14 Khor B. Regulatory T cells: Central concepts from ontogeny to therapy. Transfus Med Rev 2017; 31: 36-44
• 15 Hartmann J, Schüßler-Lent M, Bondanza A, Buchholz CJ. Clinical development of CART cells - challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med 2017; 9: 1183-1197
• 16 Schirrmacher V. Cancer-reactive memory T cells from the bone marrow: Spontaneous induction and therapeutic potential (Review). Int J Oncol 2015; 47: 2005-2016
• 17 Schirrmacher V. Quo vadis cancer therapy? Fascinating discoveries of the last 60 years. Riga: Lambert Academic Publishing; 2017
• 18 Klug F, Prakash H, Huber PE. et al. Low-dose irradiation programs macrophage differentiation to an iNOS+/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 2013; 24: 589-602
• 19 Khan KA, Kerbel RS. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol 2018; 15: 310-324. 10.1038/nrclinonc.2018.9
• 20 Chen CA, Jo CM, Chang MC. et al. Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis. Mol Ther 2010; 18: 1233-1243
• 21 Schirrmacher V, Fournier P. Oncolytic Newcastle Disease Virus as cutting edge between tumor and host. Biology (Basel).. 2013: 936-975
• 22 Schirrmacher V. Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biological agent with potential to break therapy resistance. Expert Opinion Biol Ther 2015; 15: 1757-1771
• 23 Shiozawa Y, Nie B, Pienta KJ. et al. Cancer stem cells and their role in metastasis. Pharmacol Therapy 2013; 138: 285-293
• 24 Lehmann PV, Zhang W. Unique strengths of ELISPOT for T cell diagnostics. Methods Mol Biol 2012; 792: 3-23